Cargando…

Nicotinic acid supplementation contributes to the amelioration of Alzheimer’s disease in mouse models

BACKGROUND: Alzheimer’s disease (AD) is the most common cause of dementia. Effective therapy, early diagnosis, and intervention are still lacking. Non-drug therapy and lifestyle interventions have become important means to prevent the occurrence and progression of AD, with nutritional therapy being...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhigang, Zou, Zhenyou, Li, Qinghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622504/
https://www.ncbi.nlm.nih.gov/pubmed/36330413
http://dx.doi.org/10.21037/atm-22-1148
_version_ 1784821784634195968
author Wang, Zhigang
Zou, Zhenyou
Li, Qinghua
author_facet Wang, Zhigang
Zou, Zhenyou
Li, Qinghua
author_sort Wang, Zhigang
collection PubMed
description BACKGROUND: Alzheimer’s disease (AD) is the most common cause of dementia. Effective therapy, early diagnosis, and intervention are still lacking. Non-drug therapy and lifestyle interventions have become important means to prevent the occurrence and progression of AD, with nutritional therapy being one such example. Nutritional therapy, as a non-pharmacological intervention for AD, has made significant progress and shown significant promise for the development of treatment regimens in recent years. Niacin is a critical vitamin available in the forms of nicotinamide (NAM) and nicotinic acid (NA). In tissues, niacin is transformed into nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP), which are involved in a variety of cellular processes. Recent researches indicate that niacin may be beneficial in the prevention and treatment of aging, cancer, and metabolic illnesses. METHODS: To detect the mechanism of affection of niacin in AD, we found out GSE135999 from the Gene Expression Omnibus (GEO) database which is microarray data containing samples of 24 wild-type (WT) and 24 APP/PS1 AD mice, given either nicotinamide riboside (NR; 12 mM) or nothing (CTR) in their drinking water. We conducted a more reliable data analysis method Weighted Gene Co-expression Network Analysis (WGCNA) to confirm the central players (hub genes) and related pathways associated between niacin and AD. To validate the affection of niacin in AD mice, we selected 6 WT and 12 APP/PS1 transgenic mice, the 12 APP/PS1 mice were treated with a niacin acid supplement diet or normal food. Six months later, behavioral tests were performed. RESULTS: Our research revealed the hub genes and pathways involved in the enhancement of cognition in AD animal models with niacin supplementation, through transcriptomics analysis, systems biology technique and in vivo. The hub genes were Ctnnb1, Mdm2, Crebbp, Gnb2l1/RACK1 and Pten. The related pathways were circadian rhythm, ubiquitin-mediated proteolysis, and long-term potentiation. CONCLUSIONS: A niacin supplementary diet may be a safe and simple choice for AD prevention and treatment. Niacin can enhance cognitive capacity in AD through a variety of mechanisms, among which Ctnnb1, Mdm2, Crebbp, Gnb2l1/RACK1 and Pten are significant.
format Online
Article
Text
id pubmed-9622504
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-96225042022-11-02 Nicotinic acid supplementation contributes to the amelioration of Alzheimer’s disease in mouse models Wang, Zhigang Zou, Zhenyou Li, Qinghua Ann Transl Med Original Article BACKGROUND: Alzheimer’s disease (AD) is the most common cause of dementia. Effective therapy, early diagnosis, and intervention are still lacking. Non-drug therapy and lifestyle interventions have become important means to prevent the occurrence and progression of AD, with nutritional therapy being one such example. Nutritional therapy, as a non-pharmacological intervention for AD, has made significant progress and shown significant promise for the development of treatment regimens in recent years. Niacin is a critical vitamin available in the forms of nicotinamide (NAM) and nicotinic acid (NA). In tissues, niacin is transformed into nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP), which are involved in a variety of cellular processes. Recent researches indicate that niacin may be beneficial in the prevention and treatment of aging, cancer, and metabolic illnesses. METHODS: To detect the mechanism of affection of niacin in AD, we found out GSE135999 from the Gene Expression Omnibus (GEO) database which is microarray data containing samples of 24 wild-type (WT) and 24 APP/PS1 AD mice, given either nicotinamide riboside (NR; 12 mM) or nothing (CTR) in their drinking water. We conducted a more reliable data analysis method Weighted Gene Co-expression Network Analysis (WGCNA) to confirm the central players (hub genes) and related pathways associated between niacin and AD. To validate the affection of niacin in AD mice, we selected 6 WT and 12 APP/PS1 transgenic mice, the 12 APP/PS1 mice were treated with a niacin acid supplement diet or normal food. Six months later, behavioral tests were performed. RESULTS: Our research revealed the hub genes and pathways involved in the enhancement of cognition in AD animal models with niacin supplementation, through transcriptomics analysis, systems biology technique and in vivo. The hub genes were Ctnnb1, Mdm2, Crebbp, Gnb2l1/RACK1 and Pten. The related pathways were circadian rhythm, ubiquitin-mediated proteolysis, and long-term potentiation. CONCLUSIONS: A niacin supplementary diet may be a safe and simple choice for AD prevention and treatment. Niacin can enhance cognitive capacity in AD through a variety of mechanisms, among which Ctnnb1, Mdm2, Crebbp, Gnb2l1/RACK1 and Pten are significant. AME Publishing Company 2022-10 /pmc/articles/PMC9622504/ /pubmed/36330413 http://dx.doi.org/10.21037/atm-22-1148 Text en 2022 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Wang, Zhigang
Zou, Zhenyou
Li, Qinghua
Nicotinic acid supplementation contributes to the amelioration of Alzheimer’s disease in mouse models
title Nicotinic acid supplementation contributes to the amelioration of Alzheimer’s disease in mouse models
title_full Nicotinic acid supplementation contributes to the amelioration of Alzheimer’s disease in mouse models
title_fullStr Nicotinic acid supplementation contributes to the amelioration of Alzheimer’s disease in mouse models
title_full_unstemmed Nicotinic acid supplementation contributes to the amelioration of Alzheimer’s disease in mouse models
title_short Nicotinic acid supplementation contributes to the amelioration of Alzheimer’s disease in mouse models
title_sort nicotinic acid supplementation contributes to the amelioration of alzheimer’s disease in mouse models
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622504/
https://www.ncbi.nlm.nih.gov/pubmed/36330413
http://dx.doi.org/10.21037/atm-22-1148
work_keys_str_mv AT wangzhigang nicotinicacidsupplementationcontributestotheameliorationofalzheimersdiseaseinmousemodels
AT zouzhenyou nicotinicacidsupplementationcontributestotheameliorationofalzheimersdiseaseinmousemodels
AT liqinghua nicotinicacidsupplementationcontributestotheameliorationofalzheimersdiseaseinmousemodels